Maa: Malesia
Kieli: englanti
Lähde: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
Diphtheria Toxoid; Tetanus Toxoid; PERTUSSIS TOXOID (PT); INACTIVATED POLIO VIRUS TYPE 3; INACTIVATED POLIO VIRUS TYPE 2; INACTIVATED POLIO VIRUS TYPE 1; FILAMENTOUS HAEMAGGLUTININ (FHA); PERTACTIN (PRN)
GLAXOSMITHKLINE PHARMACEUTICAL SDN. BHD.
Diphtheria Toxoid; Tetanus Toxoid; PERTUSSIS TOXOID (PT); INACTIVATED POLIO VIRUS TYPE 3; INACTIVATED POLIO VIRUS TYPE 2; INACTIVATED POLIO VIRUS TYPE 1; FILAMENTOUS HAEMAGGLUTININ (FHA); PERTACTIN (PRN)
0.5ml1Units mL
GLAXOSMITHKLINE BIOLOGICALS S.A
Not Applicable Lue koko asiakirja
-1- [GSK logo] BOOSTRIX POLIO Diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) QUALITATIVE AND QUANTITATIVE COMPOSI TION 1 dose (0.5 ml) contains: Diphtheria toxoid 1 not less than 2 International Units (IU) (2.5 Lf) Tetanus toxoid 1 not less than 20 International Units (IU) (5 Lf) Bordetella pertussis antigens Pertussis toxoid 1 8 micrograms Filamentous Haemagglutinin 1 8 micrograms Pertactin 1 2.5 micrograms Inactivated poliovirus type 1 (Mahoney strain) 2 40 D -antigen unit type 2 (MEF -1 strain) 2 8 D -antigen unit type 3 (Saukett strain) 2 32 D -antigen unit 1adsorbed on aluminium hydroxide, hydrated (Al(OH) 3) 0.3 milligrams Al 3+ and aluminium phosphate (AlPO 4) 0.2 milligrams Al 3+ 2propagated in VERO cells Boostrix Polio is a turbid white suspensi on. Upon storage, a white deposit and clear supernatant can be observed. This is a normal finding. PHARMACEUTICAL FORM Suspension for injection. CLINICAL PARTICULARS Indications Boostrix Polio is indicated for booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis of individuals from the age of four years onwards. Boostrix Polio is not intended for primary immunisation. Lue koko asiakirja